Concepedia

Author

Prafull Ghatage

University of CalgaryORCID

Also Known As

Audrey Jung, Gregg S. Nelson, Lara De Guerke, Neesha C. Dhani, P Ghatage, P. Ghatage, PRAFULL GHATAGE, Prafull Ghatage

264

Publications

9.3K

Citations

43

H-Index

59

Concepts

All Affiliations

University of CalgaryPrincess Margaret Cancer CentreUniversity of British ColumbiaPeter MacCallum Cancer CentreUniversity College London
PG

About

Prafull Ghatage is an author at University of Calgary specializing in medicine, oncology, and obstetrics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

22

34

3.5K

2

Public Health

4

4

294

3

Health Sciences

2

2

43

4

Anatomy

1

1

12

5

Cell Biology

1

1

16

Prafull Ghatage

×

73

Publications

8.2K

Citations

40

H-Index

YearCitations

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

Robert L. Coleman, Amit M. Oza, Domenica Lorusso,

The Lancet

2017

1.7K

Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial

Stephanie M. de Boer, Melanie Powell, Linda Mileshkin,

The Lancet Oncology

2018

599

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial

Stephanie M. de Boer, Melanie Powell, Linda Mileshkin,

The Lancet Oncology

2019

432

Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer

Bradley J. Monk, Thomas J. Herzog, Stanley B. Kaye,

Journal of Clinical Oncology

2010

404

Dose-Response Association of CD8<sup>+</sup> Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer

Ellen L. Goode, Matthew S. Block, Kimberly R. Kalli,

JAMA Oncology

2017

388

Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group

Amit M. Oza, Laurie Elit, Ming‐Sound Tsao,

Journal of Clinical Oncology

2011

333

Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study

Ana Oaknin, Lucy Gilbert, Anna V. Tinker,

Journal for ImmunoTherapy of Cancer

2022

300

Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials

Ignace Vergote, Corneel Coens, Matthew Nankivell,

The Lancet Oncology

2018

290

Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer

Beth Y. Karlan, Amit M. Oza, Gary Richardson,

Journal of Clinical Oncology

2011

225

Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)

Elizabeth M. Swisher, Tanya T. Kwan, Amit M. Oza,

Nature Communications

2021

193

Page 1